Sanofi and GSK progress talks with EU for 300 million COVID-19 vaccines
Sanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read moreSanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read moreResults from the ongoing Phase I/II COVID-19 vaccine trial, led by the University of Oxford, showed the AZD1222 vaccine developed
Read moreModerna’s COVID-19 vaccine candidate generated antibodies in all 45 patients studied in its early stage human trial, the U.S biotech
Read moreSanofi and GlaxoSmithKline are close to reaching a 500 million-pound ($624 million) deal to supply the United Kingdom government with
Read moreTesla Inc is engineering mobile molecule printers to help produce the future COVID-19 vaccine developed by CureVac in Germany, the
Read moreThe Chinese company Clover Biopharmaceuticals revealed the start of a randomized, double-blind, human stage Phase I placebo-controlled clinical study to
Read moreAbbVie, Harbour BioMed, Utrecht University and the Erasmus Medical Center (EMC) revealed today they have entered into a partnership to
Read moreBritish pharmaceutical company AstraZeneca has reached a landmark $750 million agreement with Coalition for Epidemic Preparedness Innovation (CEPI) and the
Read moreAstraZeneca is going to expedite the development of the University of Oxford investigational COVID-19 vaccine with a $1 billion BARDA
Read moreCEPI has increased its investment with up to $388 million for the Novavax COVID-19 (NVX‑CoV2373) vaccine development and manufacturing. Phase
Read more